MARKET

CRIS

CRIS

Curis
NASDAQ
0.3210
+0.1152
+55.98%
After Hours: 0.2900 -0.031 -9.66% 19:59 06/26 EDT
OPEN
0.2120
PREV CLOSE
0.2058
HIGH
0.3800
LOW
0.2060
VOLUME
109.83M
TURNOVER
--
52 WEEK HIGH
2.482
52 WEEK LOW
0.1806
MARKET CAP
12.51M
P/E (TTM)
-0.2684
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs 
Reuters · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
Analyst Reiterates Buy on Curis, Maintains $17 Price Target Amid Progress in TakeAim CLL Trial and Nasdaq Compliance Steps
TipRanks · 2d ago
Curis announces eleven active clinical sites in TakeAim CLL study
TipRanks · 2d ago
Curis Shareholders Approve Reverse Stock Split Effect Ratio From 1-For-5 To 1-For-25
Benzinga · 2d ago
Curis shareholders approve 1-for-5 to 1-for-25 reverse stock split proposal
PUBT · 2d ago
CURIS - REVERSE STOCK SPLIT APPROVED AT RATIO OF 1-FOR-5 TO 1-FOR-25
Reuters · 2d ago
*Curis Announces Eleven Active Clinical Sites In TakeAim CLL Study, Reaffirms Patient Dosing Guidance, And Reports Stockholder Approval Of Reverse Stock Split >CRIS
Dow Jones · 2d ago
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.